Asia Pacific Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class (Beta Blockers, Alpha Adrenergic Agonists, Prostaglandins Analogues, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), Indication (Open Angle Glauc

The Asia Pacific glaucoma therapeutics market was valued at US$ 1,211.80 million in 2023 and is expected to reach US$ 1,598.41 million by 2031; it is estimated to register a CAGR of 3.5% from 2023 to 2031.

Development of Wearable Technologies Fuels Asia Pacific Glaucoma Therapeutics Market

Technological innovation has always been fundamental to any discipline of life sciences, including ophthalmology, as modern devices are key to accurate diagnosis and improved treatments. Advancements in treatments have enabled the improved treatment of glaucoma. Wearable glaucoma diagnostics and therapeutics products have emerged as potential solutions. Conventional diagnostic techniques provide reliable intraocular pressure data, while innovative contact lenses such as Sensimed Triggerfish offer continuous IOP tracking. Advanced drug-eluting contact lenses are also emerging as a potential solution for glaucoma therapy. In March 2023, SpyGlass Pharma released 6-month data from its first-in-human glaucoma treatment trial. The data shows that its new drug delivery platform, which is a single-piece, hydrophobic acrylic intraocular lens with drug-eluting pads, continues to significantly lower IOP in patients suffering from glaucoma or ocular hypertension. Thus, the development of such modern wearable products is likely to propel the demand for glaucoma therapeutics in the coming years.

Asia Pacific Glaucoma Therapeutics Market Overview

The glaucoma therapeutics market in Asia Pacific is subsegmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Market growth in this region is ascribed to the rising incidence of glaucoma, the growing geriatric population, and surging investments to boost research activities. Key market players are adopting strategies such as mergers, acquisitions, product launches, and fundraising to expand their market presence. In February 2023, Zhaoke Ophthalmology's Bimatoprost Timolol eye drops received marketing authorization from the National Medical Products Administration (NMPA) for their use in glaucoma treatment. In February 2023, Santen Pharmaceutical Co., Ltd. received the marketing authorization from the NMPA for its application for STN1011101 eye drops. This preservative-free formulation containing tafluprost 0.0015% and timolol 0.5% was codeveloped by Santen and AGC Inc. The drug aims to address the unmet needs for glaucoma treatment in China.

A study published in the BMC Ophthalmology Journal in February 2022 reported that China has the highest rate of glaucoma in the world. Moreover, the country had 15.58 million people with all types of glaucoma in 2020, and the number is projected to spike up to 25.16 million by 2050. The high prevalence of glaucoma is expected to drive the growth of therapeutics to manage the disease in the future. The glaucoma therapeutics market growth in China is primarily attributed to various growth strategies adopted by market players and the increasing aging population.

Asia Pacific Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Glaucoma Therapeutics Market Segmentation

The Asia Pacific glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Asia Pacific glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Asia Pacific glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Asia Pacific glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Asia Pacific glaucoma therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Asia Pacific glaucoma therapeutics market.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific glaucoma therapeutics market.
Highlights key business priorities to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific glaucoma therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific glaucoma therapeutics market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.